DPP-4 inhibitors has been studied in 518 papers since 2012: 5 trials and 328 observational studies in people, 7 in animals, 1 in cells, 168 reviews; 292 in the past year. The newest story, Nov 12, 2026: “Diabetes drug class not linked to higher kidney injury risk”.
DPP-4 inhibitors are linked with lower Parkinson’s disease risk in people with diabetes, with independent labs reporting the link again, although other studies find no clear link. Independent labs report reduced inflammation in mice, and one mouse atherosclerosis study reports reduced senescent cell burden. Some authors work at companies, and some papers declare company ties.
169 findings in 111 papers from 2012 to 2026, 25 of them since April 2026
Independent labs found the same change in mice and people. 75 independent labs in 22 countries.
“DPP4i were associated with a lower risk of certain psychiatric disorders, Parkinson's disease (0.54 [0.32, 0.92])”
Mice and humans: replicated by independent labs. Cells: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
75 independent labs in 22 countries
12 findings against
Funders: National Institute on Aging and others
27 of 138 findings with company ties
Human trial5
Humans327
Animals7
Cells1
In silico6
Studies in people
4 studies gave DPP-4 inhibitors to people and measured what changed.
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·
DPP-4 inhibitors decrease inflammation in 6-OHDA lesioned rats.
“Post-treatment with a threefold higher oral gliptin dose, likewise, mitigated meth-induced rotation, dopaminergic neurodegeneration and neuroinflammation, and augmented neurogenesis.”
DPP-4 inhibitors decrease inflammation in human cells (hydrogen peroxide-treated endothelial cells).
“In vitro, the inhibition of DPP-4 also alleviated the changes in the oxidative and inflammatory molecules in response to hydrogen peroxide in human umbilical vein endothelial cells.”
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·
DPP-4 inhibitors decrease oxidative stress and ROS signaling in human cells (hydrogen peroxide-treated endothelial cells).
“In vitro, the inhibition of DPP-4 also alleviated the changes in the oxidative and inflammatory molecules in response to hydrogen peroxide in human umbilical vein endothelial cells.”
DPP-4 inhibitors are linked with lower mortality in residents of LTCFs with diabetes receiving metformin compared with long-acting insulin (sHR 0.82 (95% CI, 0.76-0.90)).
“and all-cause mortality (sHR, 0.82; 95% CI, 0.76-0.90) was observed in DPP-4 initiators compared with long-acting insulin.”
Humansin residents of LTCFs with diabetes receiving metformin compared with long-acting insulin5-year follow-upn = 4,414
DPP-4 inhibitors were not clearly linked with major adverse cardiovascular events in humans (versus sulfonylureas, used as a negative control comparison).
“We did not observe large differences in MACE or HHF risks for DPP-4i vs. SU, in line with CAROLINA trial estimates.”
Humansversus sulfonylureas, used as a negative control comparison
DPP-4 inhibitors are linked with a lower risk of dementia in humans (compared with sulfonylureas) (HR 0.77, 95% CI 0.71-0.85).
“DPP-4 inhibitors were associated with a reduced dementia risk compared with sulfonylureas (4.4 vs. 5.7 events per 1000 person-years; HR 0.77, 95% CI 0.71-0.85)”
DPP-4 inhibitors are linked with a lower risk of dementia in humans (type 2 diabetes) (HR 0.63, 95% CI 0.45-0.89).
“the utilization of DPP4 inhibitors was associated with a decreased risk of all-cause dementia compared to metformin [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.45-0.89].”
DPP-4 inhibitors are linked with a lower risk of hypoglycemia in residents of LTCFs with diabetes receiving metformin compared with long-acting insulin (sHR 0.36 (95% CI, 0.23-0.56)).
“Lower risk of hypoglycemia (sHR, 0.36; 95% CI, 0.23-0.56) and all-cause mortality (sHR, 0.82; 95% CI, 0.76-0.90) was observed in DPP-4 initiators compared with long-acting insulin.”
Humansin residents of LTCFs with diabetes receiving metformin compared with long-acting insulin5-year follow-upn = 4,414
DPP-4 inhibitors lower the risk of hypoglycemia in older adults with type 2 diabetes.
“DPP-4 inhibitors (gliptins) for their better safety profile versus sulfonylureas, GLP-1 analogues or SGLT2 inhibitors (gliflozins) if cardiorenal protection is required.”
DPP-4 inhibitors lower the risk of hypoglycemia in humans (type 2 diabetes).
“dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can be safely used in older patients and are preferred choices in many cases due to their safety, efficacy, and low risk of hypoglycemia”
DPP-4 inhibitors are linked with a higher risk of bullous pemphigoid in humans (compared with GLP-1RA in patients with type 2 diabetes) (HR 1.78, 95% CI 1.24-2.46).
“bullous pemphigoid (HR 1.78, 95% CI 1.24-2.46)”
Humanscompared with GLP-1RA in patients with type 2 diabetes3 yearsn = 118,419
DPP-4 inhibitors are linked with a higher risk of osteoporosis in humans (multivariate Cox regression; compared with metformin) (HR 1.36 (1.05–1.75)).
“For Diabetes-related risk factors, dipeptidyl peptidase-4 inhibitors (DPP4-inhibitors), insulin, and thiazolidinediones were associated with a higher risk of osteoporosis; HR were 1.36 (1.05–1.75), 1.32 (1.05–1.65), and 1.39 (1.01–1.92), respectively.”
Humansmultivariate Cox regression; compared with metforminn = 25,635
DPP-4 inhibitors are associated with cognitive function in humans (Slower MMSE decline: β = 0.772, SE = 0.272, p = 0.005; memory recall: β = 0.291, SE = 0.116, p = 0.012).
“The ADCI-DPP-4i+ group showed a slower longitudinal decrease in MMSE score (β = 0.772, SE = 0.272, p = 0.005)”
HumansPatients with diabetes and Alzheimer disease-related cognitive impairment; comparison with diabetic patients not using DPP-4 inhibitors
DPP-4 inhibitors are linked with a lower risk of bone fracture in humans (ROR = 0.80; 95% CI = 0.73 - 0.88).
“Significant inverse associations between DPP-4 inhibitor use and fracture were found for DPP-4 inhibitors as a whole (ROR = 0.80; 95% CI = 0.73 - 0.88”
International journal of clinical pharmacology and therapeutics·
DPP-4 inhibitors are associated with bone fracture in humans (some RCTs reported bone-protective effects for certain members of the class).
“Dipeptidyl peptidase-4 inhibitors (DPP-4is) and Glucagon-like peptide-1 receptor agonists (GLP-1Ras) were reported to have controversial effects on bone fracture”
Reviewsome RCTs reported bone-protective effects for certain members of the class
DPP-4 inhibitors are associated with dementia progression in humans (Patients with dementia and type 2 diabetes; compared with non-users) (Adjusted OR 0.52, 95% CI 0.33–0.82).
“Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) was associated with a significantly lower risk of dementia progression compared with non-users”
HumansPatients with dementia and type 2 diabetes; compared with non-usersn = 1,007
After statistical adjustment, kidney injury rates were 10.5 versus 15.6 per 100,000 days of patient follow-up for two diabetes drug classes over 90 days.After statistical adjustment, kidney injury rates were 10.5 versus 15.6 per 100,000 days of patient follow-up for two diabetes drug classes over 90 days.